• Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

Economics Higher Level Coursework

Extracts from this document...

Introduction

Economics Commentary 2 Section 3 Title: Novartis becomes world's biggest generic drug firm Source: Independent, The (London, England) by Rachel Stevenson In the article, the firm Novartis has taken over two other generic drug producers, namely Hexon and Eon Labs, to form the world's largest generic drug manufacturer. It will be shown that this will lower Novartis's production costs to increase profits, as the article suggests, and also that other parties will be affected in a good way. When it is said the acquisition will allow cost savings by 'bringing it to scale', the firm is having internal economies of scale (EOS) from the result of expansion of the firm. The take over in this case is a horizontal integration, with Novartis buying firms Hexon and Eon in order to acquire them, all three which are in the same production stage in generic drugs. This provides an external growth of the firm as the factors of production are acquired from the taken firms, while it does not expand its scale by investing on these factors which is more costly and takes more time. The average total costs of production (SRAC's) will decrease by expanding the scale of the firm in the long run from increasing productive efficiency, which is called economies of scale. ...read more.

Middle

It may even force some firms to exit the market and causes a barrier to the entry of new firms. Acquiring the two big firms will also mean that two major competitors leave the market. However, since the market is highly fragmented, Novartis will still only get a maximum market share of 10%, and thus its power to monopolize or set up high prices is still very limited. Generally, the decrease of generic drug prices will be good for the public as it makes these drugs readily affordable, meaning more people can attain the medical treatment they need. This will also decrease the government's expenditure in medical care as it usually buys in generic drugs, which would now be even cheaper. Clinics will have larger profits as the price of drugs they buy in decrease. Therefore the acquisition of Novartis is justified. As it would enjoy economies of scale through expansion, it could lower the prices as costs are lower. The prices would be lowered in face of competition. It can still have increased profits as costs are reduced. Thus consumers and the firm itself will benefit. February 22, 2005 Independent, The (London, England) First Section: Business Page: 34 Author: Rachel Stevenson "Novartis becomes world's biggest generic drug firm" Novartis is poised to become the world's biggest generic drug maker after agreeing to buy the German company, Hexal, and its US affiliate, Eon Labs, in a cash deal yesterday worth EUR6.4bn (pounds 4.4bn). ...read more.

Conclusion

But shares in Novartis climbed more than 3 per cent in Switzerland yesterday - a sign that investors approved the multibillion-dollar deal. Mark Clark, at Deutsche Bank, said: "Investors should be confident that Novartis is buying robust and profitable businesses with strong combined margins and decent market shares. Novartis now has critical mass in Germany, one of the largest markets for generics.... The deal looks very sensible." Novartis has about $8bn of cash on its balance sheet, and analysts have expected an acquisition for some time. The new power of Novartis in the generics market could spark other takeover deals in the sector, with rivals forced to bulk up to compete. "The generics market is fragmented," Mr. Clark said. "Even by 2010, Novartis expects to have a market share of no more than 10 per cent." Hexal, whose products include a generic version of a cholesterol-lowering drug, had sales of $1.65bn last year and commands the No. 2 spot in Germany. Eon Labs, which sells a version of GlaxoSmithKline's Wellbutrin antidepressant, is expecting to make a $30.2m profit for the last three months of 2004, up 57.3 per cent on the same period last year. Novartis will remain dominated by branded pharmaceuticals. The addition of Hexal and Eon, is expected to push revenues from generic drugs to about 15 per cent of the group's sales, compared with 10 per cent at present. ...read more.

The above preview is unformatted text

This student written piece of work is one of many that can be found in our International Baccalaureate Economics section.

Found what you're looking for?

  • Start learning 29% faster today
  • 150,000+ documents available
  • Just £6.99 a month

Not the one? Search for your essay title...
  • Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

See related essaysSee related essays

Related International Baccalaureate Economics essays

  1. Extended Essay Economics

    buy it if they have sufficient income and it is more a question of whether or not they can afford it.

  2. Growth and Development Problem Set - IB Economics exam questions and answers.

    The following are the problems: * No common unit of measurement- In some countries they use their domestic currency to measure the national income where as some countries use US dollars to measure national income. Since there are no standard unit of measurement it leads to inconsistency.

  1. Practice coursework

    Regarding the oil companies, they had to pull out staff from troubled countries, not only Libya, but other countries that are getting affected by that state, and are choosing to cut off supply as well, such as Saudi Arabia and Kuwait.

  2. Macro Economics Notes

    increases productivity levels Changes in exchange rates which makes imports more expensive Keynesians - fiscal policy This is the control of the economy through government spending and taxes.

  1. IB Economics H.L. Coursework

    will be assigned to subsidies of social programs concerning housing such as "Techo Propio". There are also resources to guarantee housing credit." "The minister said that the aim of the government is to add about 50,000 housing units to the "Techo Propio" -program, with an interest rate of 10.2% and

  2. Has the Time Come to Legalize Drugs?

    legalizing drug production and using the taxes it generates to fund anti-drug education programs, he said. ``What I'm proposing is that, instead of allowing this business to continue being run by criminals, by cartels, that it be run by law-abiding business people who are registered with the Finance Ministry, pay taxes and create jobs,'' Fox said.

  1. Buffer Stocks

    There reaches a point where a farmer can no longer produce anymore as they no longer have any more land. In the case of a glut (over production), the supply curve will shift to the right causing the price to decrease, here the government will buy and store some of

  2. 15 Historical Economic Questions on Mercatilism and the Development of European Countries.

    The stimulus plan also aimed to restore trust in the finance industry by further limiting bonuses for senior executives for companies that received TARP funds. The TARP program was born under President George W. Bush and signed into law on Oct.

  • Over 160,000 pieces
    of student written work
  • Annotated by
    experienced teachers
  • Ideas and feedback to
    improve your own work